Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12556539 | 0.68 | ALDH1A1 (0.37) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL12556538 | 0.68 | GAA (0.30) | ALDH1A1 | |
| SCHEMBL12702629 | 0.64 | ALDH1A1 (0.44) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL10205286 | 0.64 | ALDH1A1 (0.37) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL13988254 | 0.63 | ALDH1A1 (0.36) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL24417714 | 0.63 | PI4KA (0.32) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL15471719 | 0.62 | ALDH1A1 (0.32) | ALDH1A1LMNA | |
| SCHEMBL24754378 | 0.61 | ALDH1A1 (0.38) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL12246250 | 0.61 | ALDH1A1 (0.38) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A | |
| SCHEMBL24659479 | 0.61 | ALDH1A1 (0.42) | ALDH1A1LMNAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | CDK4, CDKL4, CDK2 | ALDH1A1 1917/4885LMNA 2869/4885PI4KA 401/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | ALDH1A1 1917/4885LMNA 2869/4885PI4KA 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.